Display options
Share it on

J Clin Invest. 1998 Apr 01;101(7):1509-18. doi: 10.1172/JCI171.

Fibronectin and alpha5 integrin regulate keratinocyte cell cycling. A mechanism for increased fibronectin potentiation of T cell lymphokine-driven keratinocyte hyperproliferation in psoriasis.

The Journal of clinical investigation

Z Bata-Csorgo, K D Cooper, K M Ting, J J Voorhees, C Hammerberg

Affiliations

  1. Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA.

PMID: 9525994 PMCID: PMC508729 DOI: 10.1172/JCI171

Abstract

In addition to being T lymphocyte-driven, psoriasis may be due in part to abnormal integrin expression. Normal-appearing (uninvolved) skin from psoriatic patients was examined to determine whether altered fibronectin or its receptor expression is detectable before development of psoriatic lesions. In contrast to skin from normal subjects, we detect by immunofluorescence the abnormal presence of plasma fibronectin in the basal cell layer of the epidermis of psoriatic uninvolved skin. Furthermore, increased fibronectin exposure superinduces the in vitro cell cycle induction and expansion of psoriatic nonlesional keratinocytes in response to a cocktail of T cell lymphokines. Fibronectin alone also appeared to increase cell cycle entry among uninvolved but not normal keratinocytes. Concordantly, the alpha5 integrin fibronectin receptor, but not alpha2 or alpha3, is overexpressed in the in vivo nonlesional psoriatic epidermis. The involvement of alpha5beta1 in the early outgrowth of clonogenic keratinocytes in the ex vivo culture was demonstrated by the ability of anti-alpha5 mAb to inhibit keratinocyte growth on fibronectin. Thus, the fibronectin receptor appears to be one of the components required for the development of the hyperresponsiveness of psoriatic keratinocytes to signals for proliferation provided by lymphokines produced by intralesional T lymphocytes in psoriasis.

References

  1. J Invest Dermatol. 1990 Sep;95(3):275-82 - PubMed
  2. J Clin Invest. 1997 May 1;99(9):2094-9 - PubMed
  3. J Clin Invest. 1991 Mar;87(3):878-83 - PubMed
  4. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7849-53 - PubMed
  5. J Cell Biol. 1987 Dec;105(6 Pt 2):3097-104 - PubMed
  6. Nature. 1988 Mar 24;332(6162):376-8 - PubMed
  7. Science. 1988 Jun 10;240(4858):1544-6 - PubMed
  8. Br J Dermatol. 1990 Mar;122(3):391-7 - PubMed
  9. Proc Natl Acad Sci U S A. 1990 May;87(9):3579-83 - PubMed
  10. Cell Mol Biol. 1991;37(3):253-60 - PubMed
  11. Br J Dermatol. 1991 Dec;125(6):548-56 - PubMed
  12. Cell. 1992 Apr 3;69(1):11-25 - PubMed
  13. J Cell Biol. 1992 Apr;117(2):437-47 - PubMed
  14. J Clin Invest. 1992 Jun;89(6):1783-95 - PubMed
  15. Biochim Biophys Acta. 1992 Sep 15;1117(2):126-30 - PubMed
  16. J Biol Chem. 1992 Dec 25;267(36):25744-7 - PubMed
  17. Cancer Res. 1993 Apr 1;53(7):1503-6 - PubMed
  18. J Cell Physiol. 1992 Jun;151(3):443-50 - PubMed
  19. EMBO J. 1993 May;12(5):1887-95 - PubMed
  20. J Exp Med. 1993 Oct 1;178(4):1271-81 - PubMed
  21. Development. 1993 Apr;117(4):1183-98 - PubMed
  22. J Invest Dermatol. 1993 Nov;101(5):695-700 - PubMed
  23. Am J Pathol. 1993 Nov;143(5):1458-69 - PubMed
  24. Hepatology. 1994 Jul;20(1 Pt 1):56-65 - PubMed
  25. Mol Biol Cell. 1994 Apr;5(4):389-93 - PubMed
  26. J Biol Chem. 1994 Oct 28;269(43):26602-5 - PubMed
  27. J Cell Physiol. 1994 Dec;161(3):470-82 - PubMed
  28. J Clin Invest. 1995 Jan;95(1):317-27 - PubMed
  29. Mol Biol Cell. 1994 Sep;5(9):967-75 - PubMed
  30. Science. 1995 Feb 10;267(5199):883-5 - PubMed
  31. Biochem Biophys Res Commun. 1995 Mar 8;208(1):126-34 - PubMed
  32. J Cell Biol. 1995 May;129(3):853-65 - PubMed
  33. Eur J Immunol. 1995 Apr;25(4):1018-24 - PubMed
  34. Mol Biol Cell. 1995 Mar;6(3):273-82 - PubMed
  35. J Invest Dermatol. 1966 Jan;46(1):109-16 - PubMed
  36. Cancer Res. 1978 Nov;38(11 Pt 2):4155-71 - PubMed
  37. Arch Dermatol Res. 1979 Aug;266(1):33-41 - PubMed
  38. J Invest Dermatol. 1984 Feb;82(2):150-5 - PubMed
  39. J Invest Dermatol. 1984 Jun;82(6):580-6 - PubMed
  40. Br J Dermatol. 1985 Jun;112(6):647-53 - PubMed
  41. J Invest Dermatol. 1985 Oct;85(4):304-8 - PubMed
  42. J Invest Dermatol. 1986 Sep;87(3):362-6 - PubMed
  43. J Invest Dermatol. 1986 May;86(5):585-90 - PubMed
  44. J Invest Dermatol. 1995 Jul;105(1 Suppl):89S-94S - PubMed
  45. Mol Biol Cell. 1995 Jun;6(6):725-40 - PubMed
  46. J Biol Chem. 1995 Nov 10;270(45):26794-801 - PubMed
  47. Nat Med. 1995 May;1(5):442-7 - PubMed
  48. Cell. 1995 Dec 15;83(6):957-68 - PubMed
  49. J Cell Biol. 1996 Jan;132(1-2):239-49 - PubMed
  50. Arch Dermatol Res. 1996 Aug;288(9):527-31 - PubMed
  51. Br J Dermatol. 1990 Aug;123(2):171-8 - PubMed

Substances

MeSH terms

Publication Types

Grant support